Resolved

ENALAPRILAT INJECTION USP

HIKMA CANADA LIMITED

This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.

Quick answers

Is there a shortage of ENALAPRILAT INJECTION USP in Canada?

Not currently. The most recent shortage report for ENALAPRILAT INJECTION USP 1.25MG is marked resolved (last updated September 25, 2026).

Can I still get this?Check with your pharmacist

StatusResolved

Same-ingredient products on fileNone found

Affected strength1.25MG

Last updated2026-09-25

What this means

Does this mean the shortage is completely over everywhere?

It means this specific report has been marked resolved or was avoided — but some individual pharmacies may still take time to restock.

What should I do?

If your pharmacy still doesn't have it, check with them directly — supply is expected to be normalizing.

DIN

02388499

Strength

1.25MG

Dosage Form

SOLUTION

Route

INTRAVENOUS

Active Ingredient

ENALAPRILAT

Tier

Unrated

Last Updated

2026-09-25

Reason for Shortage

Disruption of the manufacture of the drug.

Source

View original report on healthproductshortages.ca ↗

Other Products from HIKMA CANADA LIMITED

Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.

0.9% SODIUM CHLORIDE INJECTION USP

9MG · DIN 02304341

ACETYLCYSTEINE SOLUTION USP

200MG · DIN 02459906

ATROPINE INJECTION BP

0.4MG · DIN 02432188

ATROPINE INJECTION BP

0.6MG · DIN 02432196

AZACITIDINE FOR INJECTION

100MG · DIN 02507668

BACLOFEN INJECTION

2MG · DIN 02457075